Cargando…
Diagnostic and prognostic roles of circ-SHPRH for solid cancers: a meta-analysis
Background: Circ-SHPRH is a novel circular RNA which was down-regulated in various cancer tissues. Several recent studies hinted that circ-SHPRH might function as a diagnostic and prognostic biomarker for solid cancers. This meta-analysis was performed to determine the diagnostic and prognostic role...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6549407/ https://www.ncbi.nlm.nih.gov/pubmed/31213850 http://dx.doi.org/10.2147/OTT.S200755 |
_version_ | 1783424001810366464 |
---|---|
author | Li, Feng Huang, Qilin Gong, Zhenyu Wang, Hongxiang Chen, Juxiang |
author_facet | Li, Feng Huang, Qilin Gong, Zhenyu Wang, Hongxiang Chen, Juxiang |
author_sort | Li, Feng |
collection | PubMed |
description | Background: Circ-SHPRH is a novel circular RNA which was down-regulated in various cancer tissues. Several recent studies hinted that circ-SHPRH might function as a diagnostic and prognostic biomarker for solid cancers. This meta-analysis was performed to determine the diagnostic and prognostic roles of circ-SHPRH for these solid cancers. Methods: Publications were searched in PubMed, MEDLINE, Web of Science, Embase, China National Knowledge Infrastructure (CNKI), and Wanfang database. Pooled sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR), and area under the summary receiver operating characteristic curve (SROC) (AUC) with 95% confidence interval (95% CI) were calculated to evaluate the diagnostic value of circ-SHPRH. Pooled hazard ratio (HR) with 95% CI was applied to assess the prognostic value of circ-SHPRH. Results: Nine eligible studies, including 4 for diagnosis and 5 for prognosis, were included in this meta-analysis. Pooled sensitivity, specificity, PLR, NLR, DOR, and AUC were 0.79 (95% CI: 0.73–0.84), 0.75 (95% CI: 0.69–0.81), 3.20 (95% CI: 2.53–4.06), 0.28 (95% CI: 0.22–0.36), 11.27 (95% CI: 7.57–16.79), and 0.84 (95% CI: 0.80–0.87), respectively. Pooled HR indicated that low circ-SHPRH expression was significantly associated with poor overall survival (OS) (low vs high, HR=2.22, 95% CI: 1.60–3.09). Conclusion: The results of this meta-analysis indicate that circ-SHPRH might be an important diagnostic and prognostic biomarker for various solid cancers. |
format | Online Article Text |
id | pubmed-6549407 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-65494072019-06-18 Diagnostic and prognostic roles of circ-SHPRH for solid cancers: a meta-analysis Li, Feng Huang, Qilin Gong, Zhenyu Wang, Hongxiang Chen, Juxiang Onco Targets Ther Original Research Background: Circ-SHPRH is a novel circular RNA which was down-regulated in various cancer tissues. Several recent studies hinted that circ-SHPRH might function as a diagnostic and prognostic biomarker for solid cancers. This meta-analysis was performed to determine the diagnostic and prognostic roles of circ-SHPRH for these solid cancers. Methods: Publications were searched in PubMed, MEDLINE, Web of Science, Embase, China National Knowledge Infrastructure (CNKI), and Wanfang database. Pooled sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR), and area under the summary receiver operating characteristic curve (SROC) (AUC) with 95% confidence interval (95% CI) were calculated to evaluate the diagnostic value of circ-SHPRH. Pooled hazard ratio (HR) with 95% CI was applied to assess the prognostic value of circ-SHPRH. Results: Nine eligible studies, including 4 for diagnosis and 5 for prognosis, were included in this meta-analysis. Pooled sensitivity, specificity, PLR, NLR, DOR, and AUC were 0.79 (95% CI: 0.73–0.84), 0.75 (95% CI: 0.69–0.81), 3.20 (95% CI: 2.53–4.06), 0.28 (95% CI: 0.22–0.36), 11.27 (95% CI: 7.57–16.79), and 0.84 (95% CI: 0.80–0.87), respectively. Pooled HR indicated that low circ-SHPRH expression was significantly associated with poor overall survival (OS) (low vs high, HR=2.22, 95% CI: 1.60–3.09). Conclusion: The results of this meta-analysis indicate that circ-SHPRH might be an important diagnostic and prognostic biomarker for various solid cancers. Dove 2019-05-31 /pmc/articles/PMC6549407/ /pubmed/31213850 http://dx.doi.org/10.2147/OTT.S200755 Text en © 2019 Li et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Li, Feng Huang, Qilin Gong, Zhenyu Wang, Hongxiang Chen, Juxiang Diagnostic and prognostic roles of circ-SHPRH for solid cancers: a meta-analysis |
title | Diagnostic and prognostic roles of circ-SHPRH for solid cancers: a meta-analysis |
title_full | Diagnostic and prognostic roles of circ-SHPRH for solid cancers: a meta-analysis |
title_fullStr | Diagnostic and prognostic roles of circ-SHPRH for solid cancers: a meta-analysis |
title_full_unstemmed | Diagnostic and prognostic roles of circ-SHPRH for solid cancers: a meta-analysis |
title_short | Diagnostic and prognostic roles of circ-SHPRH for solid cancers: a meta-analysis |
title_sort | diagnostic and prognostic roles of circ-shprh for solid cancers: a meta-analysis |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6549407/ https://www.ncbi.nlm.nih.gov/pubmed/31213850 http://dx.doi.org/10.2147/OTT.S200755 |
work_keys_str_mv | AT lifeng diagnosticandprognosticrolesofcircshprhforsolidcancersametaanalysis AT huangqilin diagnosticandprognosticrolesofcircshprhforsolidcancersametaanalysis AT gongzhenyu diagnosticandprognosticrolesofcircshprhforsolidcancersametaanalysis AT wanghongxiang diagnosticandprognosticrolesofcircshprhforsolidcancersametaanalysis AT chenjuxiang diagnosticandprognosticrolesofcircshprhforsolidcancersametaanalysis |